Fig. 2.
Kaplan–Meier estimate of overall survival for KRAS-evaluable patients randomized to panitumumab versus patients randomized to BSC with KRAS mutant tumors
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.